These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38881370)

  • 21. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
    Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Ishigatsubo R; Mitsuhashi S; Kobayashi A; Aratake M; Saito T
    Knee Surg Sports Traumatol Arthrosc; 2017 Sep; 25(9):2929-2935. PubMed ID: 27000391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study.
    Goette A; Kwong WJ; Ezekowitz MD; Banach M; Hjortshoj SP; Zamoryakhin D; Lip GYH
    Europace; 2018 Dec; 20(12):1936-1943. PubMed ID: 29947751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
    Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
    J Am Coll Cardiol; 2018 Aug; 72(8):838-853. PubMed ID: 30115222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
    Nakamura M; Wang YQ; Wang C; Oh D; Yin WH; Kimura T; Miyazaki K; Abe K; Mercuri M; Lee LH; Segers A; Büller H
    J Thromb Haemost; 2015 Sep; 13(9):1606-14. PubMed ID: 26179767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
    Blann AD; Boriani G; Lip GY
    Europace; 2016 Oct; 18(10):1507-1513. PubMed ID: 27876695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
    Ikeda S; Koga S; Yamagata Y; Eguchi M; Sato D; Muroya T; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
    J Cardiol; 2018 Aug; 72(2):120-127. PubMed ID: 29661489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
    Kawaguchi M; Uchimura N; Okuda Y; Konuma S; Nehashi Y
    Rinsho Ketsueki; 2015 Aug; 56(8):1096-9. PubMed ID: 26345573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
    Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
    Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
    Dzeshka MS; Lip GY
    Expert Opin Pharmacother; 2015; 16(17):2661-78. PubMed ID: 26559069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wilkins R; Jin J; Chen C; Colonna P
    Pacing Clin Electrophysiol; 2022 Jan; 45(1):83-91. PubMed ID: 34662445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
    Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
    Fuji T; Fujita S; Tachibana S; Kawai Y
    J Thromb Haemost; 2010 Nov; 8(11):2458-68. PubMed ID: 20723033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
    de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
    Acta Cardiol; 2021 Jun; 76(4):431-439. PubMed ID: 33406996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.